TP53 mutation rates can reach 50% in HCC cohorts with hepatitis B virus (HBV) and aflatoxin exposure [11–13], while this percentage may decline to 10% or even lower in cohorts without exposure to such mutagens. This evidence concerns the gene TP53 and hepatocellular carcinoma.